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Where Do We Stand?*Akhilesh K. Sista, MD,y Clive Kearon, MB, PHDzSEE PAGE 1382T here have been 2 main treatments for acutepulmonary embolism (PE)—anticoagulanttherapy alone or systemic thrombolytic ther-
apy. Although systemic thrombolytic therapy is eff-
ective at preventing deaths from PE, it markedly
increases bleeding, including intracranial and fatal
bleeding (1). The recent PEITHO (Pulmonary Embo-
lism Thrombolysis Study) (2), which compared tenec-
teplase with placebo in 1,000 PE patients without
hypotension but with right ventricular dysfunction,
found no clear net beneﬁt from systemic thrombo-
lytic therapy; the reduction in cardiovascular collapse
(odds ratio: 0.30) was offset by the increase in major
bleeding (odds ratio: 5.2). Consequently, systemic
thrombolytic therapy is usually reserved for PE pa-
tients with hypotension (3). The ability to actively
remove thrombus in patients with acute PE without
increasing bleeding would be an important advance.
Catheter-based therapy has that potential.
Catheter-directed thrombolysis (CDT) was initially
developed for treatment of arterial, dialysis graft, and
deep vein thromboses (leg or arm). When used to
treat acute PE, a wire is usually passed through the
embolus, followed by placement of a multiside hole
infusion catheter through which a thrombolytic
drug is infused over 12 to 24 h (4). The delivery of the
drug directly into the thrombus is expected to be as*Editorials published in JACC: Cardiovascular Interventions reﬂect the
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contents of this paper to disclose.effective as systemic therapy but to cause less
bleeding because a much lower dose of the drug is
used. If more rapid thrombus removal is required,
such as in a decompensating patient, fragmentation,
balloon maceration, and aspiration may be used as
adjunct to CDT or instead of it (i.e., in patients with a
high risk of bleeding). These mechanical techniques,
however, are avoided in stable patients because
they may cause pulmonary artery injury. The addition
of an ultrasound-emitting wire to a multiside hole
infusion catheter is thought to accelerate thrombol-
ysis by ultrasonically disrupting thrombus (5).
Although this approach has been used to treat arterial
and deep venous thromboses for about 10 years, there
is uncertainty that the addition of ultrasound emis-
sion increases the efﬁcacy of CDT (6). Based partly on
the ﬁndings of the SEATTLE II (A Prospective, Single-
Arm Multi-Center Trial of EkoSonic Endovascular
System and Activase for Treatment of Acute Pulmo-
nary Embolism) study, which is reported in this issue
of JACC: Cardiovascular Interventions, ultrasound-
assisted CDT is now approved by the U.S. Food and
Drug Administration for treatment of acute PE (7).SEATTLE II is a single-arm prospective cohort study
in which 150 patients with lobar artery or more central
PE (31 with and 119 without hypotension) were treated
with ultrasound-assisted CDT using a standardized
protocol (7). Tissue plasminogen activator was infused
into each treated lung at a rate of 1 mg/h, to a total
dose of 24 mg (over 12 h for bilateral lung infusions),
and no additional mechanical maneuvers were used to
disrupt or aspirate thrombus. When computed to-
mography pulmonary angiography was repeated after
48 h, the right ventricular to left ventricular ratio was
decreased by 27% and thrombus burden was reduced
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1394by 30%. Pulmonary artery pressure also decreased by
27% between the start to the end of CDT. These 3 im-
provements were each highly statistically signiﬁcant.
There were 17 episodes of major bleeding in 15 patients
(10%): one was associated with hypotension; all re-
quired transfusion; none was intracranial; and none
was fatal. Strengths of the SEATTLE II study include its
prospective design, inclusion of 150 patients, high
patient retention, involvement of many clinical cen-
ters, standardized treatment protocol, and rigorous
reporting. Limitations include that there was no
comparison group (neither anticoagulation alone nor
systemic thrombolytic therapy), short-term surrogate
outcomes were used to assess efﬁcacy, and that long-
term outcomes such as quality of life or exercise ca-
pacity were not assessed. SEATTLE II also did not
assess whether ultrasound-assisted CDT was more
effective than standard CDT.
So, how effective and safe is CDT? The short-
term improvements in right ventricular dimensions,
thrombus burden, and pulmonary hypertension in
SEATTLE II are consistent with the improvement
in right ventricular dimension with ultrasound-
facilitated CDT in 35 patients in the ULTIMA (Ultra-
sound Accelerated Thrombolysis of Pulmonary
Embolism) study (8). In ULTIMA, there was almost no
improvement in this outcome at 24 h in the 35 pa-
tients who were randomized to anticoagulant therapy
alone, and the difference between the CDT and anti-
coagulant therapy alone groups was highly statisti-
cally signiﬁcant. A recently published prospective
registry of 101 patients with acute PE (PERFECT
[Pulmonary Embolism Response to Fragmentation,
Embolectomy, and Catheter Thrombolysis]) (9) re-
ported similar efﬁcacy of CDT, with or without
ultrasound-assisted thrombolysis, to ULTIMA and
SEATTLE. There was no major bleeding in this re-
gistry, although follow-up may not have been as
standardized as the follow-up for the SEATTLE II
and ULTIMA studies. The improvements in imaging
and pulmonary artery pressure with ultrasound-
assisted CDT in SEATTLE II and ULTIMA also appear
to be at least as marked as the short-term improve-
ments in these outcomes with systemic thrombolytic
therapy (10). Therefore, based mostly on indirectcomparisons of short-term surrogate outcomes, CDT
appears to be effective compared with anticoagulant
therapy alone and probably is as effective as systemic
thrombolytic therapy, which uses much higher dose
of the thrombolytic drug. The frequency of major
bleeding in SEATTLE II, however, suggests that CDT
may be associated with substantially more bleeding
than anticoagulation alone. Although it is encour-
aging that there were no intracranial bleeds in the 150
patients in SEATTLE II, the upper boundary of the
95% conﬁdence interval on this estimate is 2.4%.
Although it seems likely that there is a lower risk of
nonprocedural bleeding with CDT than with systemic
thrombolytic therapy, this remains uncertain.
What then is the role of CDT in patients with PE?
We think that current evidence suggests that CDT is
preferred to systemic thrombolytic therapy in pa-
tients with acute PE who require active thrombus
removal and have risk factors for bleeding. We sug-
gest that venous puncture for CDT should always be
ultrasound-guided and that the total dose of throm-
bolytic drug should be kept to a minimum in patients
with a high risk of bleeding (3). If there is need for
active thrombus removal in patients with a very
high risk of bleeding, it may be necessary to use
catheter-based therapy without thrombolytic drug
or to use surgical embolectomy. We are not ready
to encourage use of CDT in preference to anti-
coagulation alone in stable patients with acute PE
and right ventricular dysfunction. We suggest that
there is a need for evidence that the short- and long-
term beneﬁts of CDT outweigh the associated risk of
bleeding before CDT can be recommended for such
patients. We encourage randomized trials that
compare CDT with systemic thrombolytic therapy in
unstable patients with PE and compare CDT with
anticoagulation alone in stable patients who have
large PE and right ventricular dysfunction. Evidence
from such studies would place the role of CDT for PE
on a ﬁrmer footing.
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